Nivolumab plus first-line therapy for advanced Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have just been diagnosed with advanced Hodgkin lymphoma (stage IIB with bulky disease, III, or IV).
- You have not had any prior treatment for lymphoma, such as chemotherapy, radiation, or immunotherapy.
- You are between 18 and 60 years old.
- You are in reasonably good health (able to do daily activities and not bedridden more than half the day).
- You do not have an active autoimmune disease, active hepatitis B or C, HIV, or other serious health issues like heart failure or severe lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests adding tislelizumab (an immune medicine) to standard first-line chemotherapy for people age 60 and older with newly diagnosed classic Hodgkin lymphoma. The goal is to improve how well treatment works while adapting the plan for older adults.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.